Construction of the Interaction Network of Hub Genes in the Progression of Barrett’s Esophagus to Esophageal Adenocarcinoma

References

• Lin Y, Wang HL, Fang K, Zheng Y, Wu J. International trends in esophageal cancer incidence rates by histological subtype (1990–2012) and prediction of the rates to 2030. Esophagus. 2022;19(4):560–568. doi:10.1007/s10388-022-00927-4
   PubMed Web of Science ®Google Scholar
• Wang S, Zheng R, Arnold M, et al. Global and national trends in the age-specific sex ratio of esophageal cancer and gastric cancer by subtype. Int J Cancer. 2022;151(9):1447–1461. doi:10.1002/ijc.34158
   PubMed Web of Science ®Google Scholar
• Nealis TB, Washington K, Keswani RN. Endoscopic therapy of esophageal premalignancy and early malignancy. J Natl Compr Canc Netw. 2011;9(8):890–899. doi:10.6004/jnccn.2011.0073
   PubMedGoogle Scholar
• Shaheen NJ, Smith MS, Odze RD. Progression of Barrett’s esophagus, crypt dysplasia, and low-grade dysplasia diagnosed by wide-area transepithelial sampling with 3-dimensional computer-assisted analysis: a retrospective analysis. Gastrointest Endosc. 2022;95(3):410–418e1. doi:10.1016/j.gie.2021.09.014
   PubMedGoogle Scholar
• Peleg N, Schmilovitz-Weiss H, Shamah S, Schwartz A, Dotan I, Sapoznikov B. Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett’s esophagus. Endoscopy. 2021;53(8):774–781. doi:10.1055/a-1292-8747
   PubMedGoogle Scholar
• Steele D, Baig KKK, Peter S. Evolving screening and surveillance techniques for Barrett’s esophagus. World J Gastroenterol. 2019;25(17):2045–2057. doi:10.3748/wjg.v25.i17.2045
   PubMedGoogle Scholar
• Beveridge CA, Mittal C, Muthusamy VR, et al. Identification of visible lesions during surveillance endoscopy for Barrett’s esophagus: a video-based survey study. Gastrointest Endosc. 2023;97(2):241–247 e2. doi:10.1016/j.gie.2022.08.024
   PubMedGoogle Scholar
• Maione F, Chini A, Maione R, et al. Endoscopic diagnosis and management of barrett’s esophagus with low-grade dysplasia. Diagnostics. 2022;12(5):1295. doi:10.3390/diagnostics12051295
   Google Scholar
• Amano Y, Ishimura N, Ishihara S. Is malignant potential of barrett’s esophagus predictable by endoscopy findings? Life. 2020;10(10):244. doi:10.3390/life10100244
   PubMedGoogle Scholar
• Helminen O, Melkko J, Saarnio J, et al. Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case-control study. Virchows Arch. 2022;481(3):467–476. doi:10.1007/s00428-022-03340-5
   PubMedGoogle Scholar
• Januszewicz W, Pilonis ND, Sawas T, et al. The utility of P53 immunohistochemistry in the diagnosis of Barrett’s oesophagus with indefinite for dysplasia. Histopathology. 2022;80(7):1081–1090. doi:10.1111/his.14642
   PubMedGoogle Scholar
• Bowman CJ, Zhang R, Balitzer D, et al. Persistent or recurrent Barrett’s neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue. Mod Pathol. 2021;34(10):1889–1900. doi:10.1038/s41379-021-00832-8
   PubMedGoogle Scholar
• Ireland CJ, Thrift AP, Esterman A. Risk prediction models for barrett’s esophagus discriminate well and are generalizable in an external validation study. Dig Dis Sci. 2020;65(10):2992–2999. doi:10.1007/s10620-019-06018-2
   PubMedGoogle Scholar
• Faghani S, Codipilly DC, David V, et al. Development of a deep learning model for the histologic diagnosis of dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2022;96(6):918–925 e3. doi:10.1016/j.gie.2022.06.013
   PubMedGoogle Scholar
• van der Ende-van Loon MCM, Nieuwkerk PT, van Stiphout SHC, et al. Barrett Esophagus: quality of life and factors associated with illness perception. United Euro Gastroenterol J. 2022;10(7):721–729. doi:10.1002/ueg2.12266
   PubMedGoogle Scholar
• Milano F, van Baal JW, Buttar NS, et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology. 2007;132(7):2412–2421. doi:10.1053/j.gastro.2007.03.026
   PubMed Web of Science ®Google Scholar
• Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett’s metaplasia. Am J Physiol Gastrointest Liver Physiol. 2008;295(2):G211–8. doi:10.1152/ajpgi.90250.2008
   PubMed Web of Science ®Google Scholar
• Avissar NE, Toia L, Hu Y, et al. Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR). J Gastrointest Surg. 2009;13(2):212–222. doi:10.1007/s11605-008-0720-7
   PubMedGoogle Scholar
• Chen L, Lu H, Peng D, et al. Activation of NOTCH signaling via DLL1 is mediated by APE1-redox-dependent NF-kappaB activation in oesophageal adenocarcinoma. Gut. 2023;72(3):421–432. doi:10.1136/gutjnl-2022-327076
   PubMed Web of Science ®Google Scholar
• Yen CJ, Izzo JG, Lee DF, et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett’s-associated esophageal adenocarcinoma. Cancer Res. 2008;68(8):2632–2640. doi:10.1158/0008-5472.CAN-07-5460
   PubMedGoogle Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Li K, Zhang J, Tian Y, et al. The Wnt/beta-catenin/VASP positive feedback loop drives cell proliferation and migration in breast cancer. Oncogene. 2020;39(11):2258–2274. doi:10.1038/s41388-019-1145-3
   PubMedGoogle Scholar
• Li K, Wang Q, Bian H, et al. Comprehensive analysis reveals USP45 as a novel putative oncogene in pan-cancer. Front Mol Biosci. 2022;9:886904. doi:10.3389/fmolb.2022.886904
   PubMedGoogle Scholar
• Louie BH, Kato S, Kim KH, et al. Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy. NPJ Prec Oncol. 2022;6(1):67. doi:10.1038/s41698-022-00309-0
   PubMedGoogle Scholar
• Eluri S, Reddy S, Ketchem CC, et al. Low prevalence of endoscopic screening for barrett’s esophagus in a screening-eligible primary care population. Am J Gastroenterol. 2022;117(11):1764–1771. doi:10.14309/ajg.0000000000001935
   PubMedGoogle Scholar
• Venkitachalam S, Babu D, Ravillah D, et al. The Ephrin B2 receptor tyrosine kinase is a regulator of proto-oncogene MYC and molecular programs central to barrett’s Neoplasia. Gastroenterology. 2022;163(5):1228–1241. doi:10.1053/j.gastro.2022.07.045
   PubMedGoogle Scholar
• Roumans CAM, Zellenrath PA, Steyerberg EW, et al. Sex differences in neoplastic progression in barrett’s esophagus: a multicenter prospective cohort study. Cancers. 2022;14(13):3240. doi:10.3390/cancers14133240
   PubMedGoogle Scholar
• Sundaram S, Kim EN, Jones GM, et al. Deciphering the immune complexity in esophageal adenocarcinoma and pre-cancerous lesions with sequential multiplex immunohistochemistry and sparse subspace clustering approach. Front Immunol. 2022;13:874255. doi:10.3389/fimmu.2022.874255
   PubMedGoogle Scholar
• Cekani E, Epistolio S, Dazio G, et al. Molecular biology and therapeutic perspectives for K-Ras mutant non-small cell lung cancers. Cancers. 2022;14(17):4103. doi:10.3390/cancers14174103
   PubMedGoogle Scholar
• Vedantam S, Katona BW, Sussman DA, Kumar S. Outcomes of upper endoscopy screening in Lynch syndrome: a meta-analysis. Gastrointest Endosc. 2023;97(1):2–10 e1. doi:10.1016/j.gie.2022.08.040
   PubMedGoogle Scholar
• Kim JS, Kim BG, Hwang SH. Efficacy of artificial intelligence-assisted discrimination of oral cancerous lesions from normal mucosa based on the oral mucosal image: a systematic review and meta-analysis. Cancers. 2022;14(14). doi:10.3390/cancers14143499
   Google Scholar
• Ribeiro R, Carvalho MJ, Goncalves J, Moreira JN. Immunotherapy in triple-negative breast cancer: insights into tumor immune landscape and therapeutic opportunities. Front Mol Biosci. 2022;9:903065. doi:10.3389/fmolb.2022.903065
   PubMedGoogle Scholar
• Wang L, Xu T, Yang X, et al. Immunosuppression induced by glutamine deprivation occurs via activating PD-L1 transcription in bladder cancer. Front Mol Biosci. 2021;8:687305. doi:10.3389/fmolb.2021.687305
   PubMedGoogle Scholar
• Gan X, Shan Q, Li H, et al. An anti-CTLA-4 heavy chain-only antibody with enhanced T(reg) depletion shows excellent preclinical efficacy and safety profile. Proc Natl Acad Sci USA. 2022;119(32):e2200879119. doi:10.1073/pnas.2200879119
   PubMedGoogle Scholar
• Takahashi K, Kurashina K, Yamaguchi H, et al. Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer. Front Immunol. 2022;13:969468. doi:10.3389/fimmu.2022.969468
   PubMedGoogle Scholar
• Sukri A, Hanafiah A, Kosai NR. The roles of immune cells in gastric cancer: anti-cancer or pro-cancer? Cancers. 2022;14(16):3922. doi:10.3390/cancers14163922
   PubMedGoogle Scholar